[go: up one dir, main page]

WO1996041641A1 - Compositions pharmaceutiques presentant une activite analgesique - Google Patents

Compositions pharmaceutiques presentant une activite analgesique Download PDF

Info

Publication number
WO1996041641A1
WO1996041641A1 PCT/EP1996/002472 EP9602472W WO9641641A1 WO 1996041641 A1 WO1996041641 A1 WO 1996041641A1 EP 9602472 W EP9602472 W EP 9602472W WO 9641641 A1 WO9641641 A1 WO 9641641A1
Authority
WO
WIPO (PCT)
Prior art keywords
analgesic activity
pharmaceutical compositions
perchloric acid
extracting
liver
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/EP1996/002472
Other languages
English (en)
Inventor
Alberto Bartorelli
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zetesis SpA
Original Assignee
Zetesis SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zetesis SpA filed Critical Zetesis SpA
Priority to AU62234/96A priority Critical patent/AU6223496A/en
Publication of WO1996041641A1 publication Critical patent/WO1996041641A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Definitions

  • the present invention relates to pharmaceutical formulations with analgesic activity containing as active ingredient polypeptides obtainable by extraction of mammal liver, particularly goat liver, with perchloric acid.
  • polypeptides which can be used according to the invention are disclosed in EP 574 394 as potent antineoplastic agents.
  • EP 574 394 the effectiveness of said polypeptides in controlling tumor-related pain is described.
  • compositions of the invention will preferably contain the goat liver extract defined in EP 574 394 with the abbreviation L6E, essentially consisting of three main protein components with molecular weights of 50,000, 14,000 and 10,000 daltons in SDS-PA6E, or the single protein components with molecular weights of 50,000 and/or 14,000 and/or 10,000.
  • compositions will be preferably administered by the parenteral route, for example intramuscularly or subcutaneously, in the form of sterile solutions or suspensions.
  • parenteral route for example intramuscularly or subcutaneously
  • examples of said formulations comprise vials or ampoules containing the freeze-dried ingredient to be dissolved before use with physiological sterile solutions, solutions or suspensions in sterile aqueous or oily solvents suitable to the in vivo administration.
  • the daily dosage, related to the LGE extract will typically range from 0.1 to 20 mg of extract (or the equivalent of the components thereof) .
  • the central analgesic activity is particularly fast and it is not accompanied by tolerance and/or addiction phenomena.
  • Analgesic thresholds were evaluated using the hot plate test (56*C). LGE was administered subcutaneously to normal Sprague Dawley rats (Charles River, Calco, CO) at the doses reported in the table.
  • the hot plate test evidences a "central" analgesic effect.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La présente invention se rapporte à des compositions pharmaceutiques présentant une activité analgésique, contenant comme principe actif des polypeptides obtenus par extraction du foie d'un animal à l'aide d'acide perchlorique.
PCT/EP1996/002472 1995-06-13 1996-06-07 Compositions pharmaceutiques presentant une activite analgesique Ceased WO1996041641A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU62234/96A AU6223496A (en) 1995-06-13 1996-06-07 Pharmaceutical compositions with analgesic activity

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT95MI001253A IT1276707B1 (it) 1995-06-13 1995-06-13 Composizioni farmaceutiche ad attivita' analgesica
ITMI95A001253 1995-06-13

Publications (1)

Publication Number Publication Date
WO1996041641A1 true WO1996041641A1 (fr) 1996-12-27

Family

ID=11371805

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1996/002472 Ceased WO1996041641A1 (fr) 1995-06-13 1996-06-07 Compositions pharmaceutiques presentant une activite analgesique

Country Status (4)

Country Link
AU (1) AU6223496A (fr)
IT (1) IT1276707B1 (fr)
WO (1) WO1996041641A1 (fr)
ZA (1) ZA964954B (fr)

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992010197A1 (fr) * 1990-12-11 1992-06-25 Zetesis S.P.A. Substances a caractere polypeptidique utiles a la therapeutique chez l'homme
WO1996002567A1 (fr) * 1994-07-14 1996-02-01 Zetesis S.P.A. Proteines extraites du foie de mammiferes et leur utilisation en oncologie

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992010197A1 (fr) * 1990-12-11 1992-06-25 Zetesis S.P.A. Substances a caractere polypeptidique utiles a la therapeutique chez l'homme
WO1996002567A1 (fr) * 1994-07-14 1996-02-01 Zetesis S.P.A. Proteines extraites du foie de mammiferes et leur utilisation en oncologie

Also Published As

Publication number Publication date
AU6223496A (en) 1997-01-09
ZA964954B (en) 1997-01-23
ITMI951253A0 (it) 1995-06-13
ITMI951253A1 (it) 1996-12-13
IT1276707B1 (it) 1997-11-03

Similar Documents

Publication Publication Date Title
EP0185472B1 (fr) Compositions analgésiques
KR0164435B1 (ko) 비만증 치료용 약제학적 조성물
CA2093806A1 (fr) Methode de traitement ou de prevention du diabete de type 1 par l'administration orale d'insuline
KR100397034B1 (ko) 비강투여용비무기식염용액
CA2376978A1 (fr) Compositions et methodes de traitement de dysfonctionnements sexuels
US8003696B2 (en) Composition and method for treating bacterial, viral, fungal diseases, inflammation and pain
Gorski et al. Potent antinociceptive activity of a hydroalcoholic extract of Phyllanthus corcovadensis
DE69929330T2 (de) Neue verwendung von hiv-protease hemmern
ATE254463T1 (de) Verwendung von valaciclovir zur herstellung eines arzneimittels zur behandlung von genitalherpes durch einmal tägliche verabreichung
HU228799B1 (en) Tanacetum parthenium extract
RU2207140C2 (ru) Применение экстрактов гинкго двудольного для приготовления лекарственного средства
WO1996041641A1 (fr) Compositions pharmaceutiques presentant une activite analgesique
US20070134355A1 (en) Use of plant parts of prickly pear (opuntia) and/or extracts therefrom for the treatment of depressions
US20240299481A1 (en) Stephania cepharantha-derived alkaloid-containing preparation
KR20040013150A (ko) 근육감소증 치료용 의약 제조를 위한 은행나무 추출물의용도
CA2361081A1 (fr) Traitement de la sclerose en plaques a la chaperonine 10 et au .beta.-interferon
WO1995022324A1 (fr) Traitement des cephalees migraineuses et formulations
HUP0200127A2 (en) Sustained release salts of pharmaceutically active peptides and process for their production
JPH08310944A (ja) 肝疾患治療剤
Broccardo Development of tolerance to the effect of dermophin on gastric emptying in the rat
US5916924A (en) Remedies for liver diseases
Pontani et al. Potentiation of morphine analgesia by subanesthetic doses of pentobarbital
WO2007132280A1 (fr) Isatine et dérivés convenant comme médicaments
CA2081808A1 (fr) Combinaison d'antagonistes du calcium avec des inhibiteurs de la cholinesterase
JPH0543472A (ja) 抗消化性潰瘍剤とその製造方法

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AU AZ BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IL IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TM TR TT UA UG US UZ VN AM AZ BY KG KZ MD RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA